2 weeks Ago
Jubilant Pharmova Q2 Results Live : Jubilant Pharmova declared their Q2 results on October 25, 2024, revealing a notable increase in profitability. The company's topline surged by 4.28% year-over-year, while profits skyrocketed by 64.
48%. Despite the positive year-over-year results, there was a slight decline compared to the previous quarter, where revenue experienced a growth of only 1.19% and profit saw a significant drop of 78.
68%. In terms of expenses, the Selling, General & Administrative expenses increased by 2.06% quarter-over-quarter and rose by 6.
11% year-over-year. This uptick in expenses may have contributed to the reduction in operating income, which was down by 66.98% from the previous quarter, though it did see an increase of 26.
58% year-over-year. The Earnings Per Share (EPS) for Q2 was reported at ₹ 7.09, reflecting an impressive growth of 80.
04% compared to the same quarter last year. Investors might find this figure encouraging as it indicates a solid increase in profitability on a per-share basis. In the past week, Jubilant Pharmova has faced a slight dip, delivering a return of -5.
57%. However, the company has shown a remarkable recovery over a longer timeframe, with a return of 63.48% over the last six months and an impressive 103.
14% year-to-date. This performance has led to a market capitalization of ₹ 17,551.15 Cr, with a 52-week high of ₹ 1247.
15 and a low of ₹ 318.75. Looking ahead, the sentiment among analysts remains positive.
As of October 26, 2024, out of three analysts covering the company, one has given a 'Buy' rating while two have assigned a 'Strong Buy' rating. The consensus recommendation is to 'Strong Buy', indicating confidence in the company's future performance. Jubilant Pharmova Financials.
